Imaging of Systemic Light Chain Cardiac Amyloidosis and Whole-Body Amyloidosis

Overview

About this study

The objective of our study is to develop [11C]PIB PET as a new imaging biomarker for quantitative assessment of AL cardiac amyloidosis. The hypothesis is the degree of amyloid deposition in the myocardium and other organs in whole body could be detected and quantified by [11C]PIB PET imaging, which will diagnose cardiac amyloidosis early, differentiate AL cardiac amyloidosis from others, and monitor therapy response. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with diagnosis of light-chain (AL) or transthyretin-related (TTR) cardiac amyloidosis will be included in the study.
  • Males and females over the age of 18 years.
  • Women of childbearing potential with a negative urine pregnancy test.

Exclusion Criteria: 

  • Males and females under the age of 18 years.
  • Pregnant subjects will be excluded from the study.
  • Participants that are unable to sign consent forms.
  • Patient with claustrophobia who cannot tolerate PET/CT procedure.
  • Patients with intracardiac leads or devices. 

Eligibility last updated 9/1/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Manoj Jain, M.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available